Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

A groundbreaking study has revealed that the immune system plays a crucial role in determining the survival chances of cancer ...

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Every year, the Leukemia & Lymphoma Society (LLS) organizes various fundraisers to support its mission and raise awareness ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

It’s NASCAR’s turn to throw its version of the Super Bowl, and the Daytona 500 is trying hard to match the hype, though the ...